As the Right to Try Act of 2017 moves from Senate approval to the House floor, the FDA continues to facilitate expanded access to investigational drugs for terminally ill patients with streamlined case review and clarified instructions for adverse event reports.
“The Right to Try Act is an alternative pathway. I don't think it's necessarily there to replace the FDA Expanded Access program currently in place,” Neha K. Patel, PharmD, associate at Arnold & Porter Kaye Scholer LLP, told Healio.com/Hepatology. “There are pros and cons to having an individual patient (Read more...)
Uncategorized